CBI will hold a Pharma/Bio Forum on Preclinical Development titled “Utilize Biomarkers and Leverage Partnerships for Earlier Toxicity Detection.” The conference will take place on September 26-27 at the Hyatt Harborside in Boston, MA.
This scientific 2-day conference will cover:
Translational capabilities for accelerated research
Innovative metabolic and oncologic therapeutics
Beneficial partnerships with academia and CROs
Biomarker assessment and preclinical toxicity considerations
Over the past several years, drug discovery and preclinical R&D have been severely affected by the recession cuts. Going forward, the industry looks to strategically utilize available resources for their preclinical development in a cost-effective and timely manner. This conference assesses available opportunities for bio/pharmaceutical companies to accelerate research, utilize R&D technology and leverage partnerships throughout development. Specific considerations include: biomarkers, translational research, orphan drugs and global development.
10 KEY BENE FIT S OF ATTENDING:
1. Steps you can take to strengthen your IND submissions
2. Learn what both sides of in-licensing and out-licensing need to know
3. Understand how Merrimack Pharmaceuticals is using human stem cell-derived cardiomyocytes
4. Examine preclinical considerations in the discovery of novel oncology therapeutics
5. Leverage partnerships with academic institutions
6. Use efficacy and safety biomarkers in preclinical studies
7. Develop regulatory and safety strategies for novel constructs
8. Explore how VIA Pharmaceuticals is developing a novel thyroid hormone agonist
9. Structure an exploratory strategy at lead optimization
10. Identify drivers for recent growth of orphan drug development at Pfizer
For more information or to register, please visit the CBI website.
